Company Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.
The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn’s disease.
It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.
In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson’s disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease.
Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 21, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 83 |
| CEO | Raju Mohan |
Contact Details
Address: 12790 El Camino Real, Suite 200 San Diego, California 92130 United States | |
| Phone | 760 593 4832 |
| Website | ventyxbio.com |
Stock Details
| Ticker Symbol | VTYX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001851194 |
| CUSIP Number | 92332V107 |
| ISIN Number | US92332V1070 |
| Employer ID | 83-2996852 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raju S. Mohan Ph.D. | Founder, Chief Executive Officer, President and Director |
| Dr. Sheila K. Gujrathi M.D. | Executive Chairperson |
| Matthew Richard Moore | Chief Operating Officer |
| Dr. Mark S. Forman M.D., Ph.D. | Chief Medical Officer |
| Roy M. Gonzales CPA, M.B.A. | Senior Vice President of Finance and Principal Financial and Accounting Officer |
| Dr. John M. Nuss Ph.D. | Chief Scientific Officer |
| Snehal Naik Ph.D. | Senior Vice President of Clinical Development |
| Kathy Ogilvie Ph.D. | Senior Vice President of Translational and Nonclinical Research |
| Arline Nakanishi | Senior Vice President of Biometrics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2026 | SCHEDULE 13D/A | Filing |
| Mar 4, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 4, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 4, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 4, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 4, 2026 | POS AM | Post-Effective amendments for registration statement |
| Mar 4, 2026 | POS AM | Post-Effective amendments for registration statement |
| Mar 4, 2026 | 25-NSE | Filing |
| Mar 4, 2026 | 8-K | Current Report |
| Mar 3, 2026 | 8-K | Current Report |